Vertex and CRISPR Therapeutics to co-develop and co-commercialize CTX001 for SCD
Vertex and CRISPR Therapeutics announced the companies will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as part of the companies' previously announced collaboration aimed at development of new gene editing treatments that use CRISPR/Cas9 technology. December 12, 2017